Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has been shown to be effective against severe coronavirus disease 2019. However, this vaccine induces lower severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)–specific antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Geers, Daryl, Schmitz, Katharina S., Garcia Garrido, Hannah M., Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Lafeber, Melvin, van Baarle, Debbie, GeurtsvanKessel, Corine H., de Vries, Rory D., van der Kuy, P. Hugo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796791/
https://www.ncbi.nlm.nih.gov/pubmed/35045226
http://dx.doi.org/10.1056/NEJMoa2116747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796791/
https://www.ncbi.nlm.nih.gov/pubmed/35045226
http://dx.doi.org/10.1056/NEJMoa2116747

Ejemplares similares